If you or a loved one is taking Tysabri, the risk of Progressive Multifocal Leukoencephalopathy (PML) is a serious concern. The scientific evidence clearly establishes an association, but important uncertainties remain about individual risk prediction and causation. Building on decades of pharmacovigilance research, this page examines what is known—and what is not yet known—about Tysabri and PML.
Building on the foundational understanding of therapeutic risk, we now focus specifically on Tysabri (natalizumab) and its established association with PML. Tysabri is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The association between Tysabri and PML is established through clinical trial data, post-marketing surveillance, and mechanistic understanding. This section provides a detailed examination of the clinical presentation, pharmacological profile, and mechanistic pathways linking Tysabri to PML, drawing on authoritative sources such as the FDA-approved prescribing information.
PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring in immunocompromised individuals. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain imaging, typically MRI showing white matter lesions, and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because prompt intervention may improve outcomes.
Tysabri is indicated as monotherapy for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Crohn's disease, it should not be used with immunosuppressants or TNF-alpha inhibitors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug works by blocking alpha-4 integrin, preventing immune cells from crossing the blood-brain barrier. This mechanism reduces inflammation but also impairs immune surveillance in the central nervous system. Adverse reactions reported in clinical trials include headache, influenza-like illness, peripheral edema, toothache, infections such as influenza and sinusitis, cough, back pain, and dysmenorrhea (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Notably, PML occurred in three patients in clinical trials: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both also received interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanism linking Tysabri to PML involves impaired immune surveillance. By blocking lymphocyte trafficking to the brain, Tysabri reduces the ability of the immune system to control JC virus reactivation. The JC virus is latent in many individuals, but when immune control is compromised, it can replicate and cause demyelinating lesions characteristic of PML. This mechanism is supported by the observation that risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The prescribing information for Tysabri includes a boxed warning highlighting the increased risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning states that PML usually leads to death or severe disability and identifies three risk factors: anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These warnings are comprehensive and emphasize the need for risk-benefit assessment before initiating treatment.
For patients who develop PML while on Tysabri, causation is supported by the known biological mechanism and epidemiological evidence. The presence of anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use are established risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, not all patients with these risk factors develop PML, indicating that other factors may contribute. The clinical trials documented PML cases in patients receiving Tysabri, including those also on interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For affected patients, establishing causation involves evaluating the timeline of exposure, presence of risk factors, and exclusion of other causes.
The timeline between Tysabri exposure and PML onset varies. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period is consistent with the time needed for JC virus reactivation and progression to clinical disease. Prompt recognition and withholding of Tysabri at the first sign of PML are critical to potentially reduce harm.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is associated with an increased risk of PML, a severe brain infection caused by the JC virus. The drug impairs immune surveillance in the central nervous system, allowing JC virus reactivation. Risk factors include anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior immunosuppressant use. The prescribing information includes a boxed warning about this risk.
PML diagnosis involves brain imaging (MRI showing white matter lesions) and detection of JC virus DNA in cerebrospinal fluid. Clinical symptoms include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Early recognition is critical for potential intervention.
If you experience any new neurological symptoms, contact your healthcare provider immediately. Tysabri should be withheld at the first sign of PML. The drug is only available through the TOUCH Prescribing Program, which includes monitoring requirements.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.